View on Pubmed.gov 25427174 | View on doi.org 10.4161/1942086...
Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.
- a Institute of Biomedical Sciences ; Fudan University ; Shanghai , China.
Abstract
SM03, a chimeric antibody that targets the B-cell restricted antigen CD22, is currently being clinically evaluated for the treatment of lymphomas and other autoimmune diseases in China. SM03 binding to surface CD22 leads to rapid internalization, making the development of an appropriate cell-based bioassay for monitoring changes in SM03 bioactivities during production, purification, storage, and clinical trials difficult. We report herein the development of an anti-idiotype antibody against SM03. Apart from its being used as a surrogate antigen for monitoring SM03 binding affinities, the anti-idiotype antibody was engineered to express as fusion proteins on cell surfaces in a non-internalizing manner, and the engineered cells were used as novel "surrogate target cells" for SM03. SM03-induced complement-mediated cytotoxicity (CMC) against these "surrogate target cells" proved to be an effective bioassay for monitoring changes in Fc functions, including those resulting from minor structural modifications borne within the Fc-appended carbohydrates. The approach can be generally applied for antibodies that target rapidly internalizing or non-surface bound antigens. The combined use of the anti-idiotype antibody and the surrogate target cells could help evaluate clinical parameters associated with safety and efficacies, and possibly the mechanisms of action of SM03.
References
Lancet Oncol. 2012 Apr;13(4):403-11
J Immunol. 1989 Oct 15;143(8):2595-601
Cell Mol Life Sci. 2013 Apr;70(8):1319-34
J Pharm Sci. 2007 Jan;96(1):1-26
Cited by 3 citations (total)
Clinical Trial, Phase I Journal Article Multicenter Study
Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.
Electronic publication date January 4, 2017
Qian Zhao [...] Pei Hu et al.
BACKGROUND AND OBJECTIVES
SM03 is a novel recombinant, human/mouse chimeric immunoglobulin G1 monoclonal antibody directed against the CD22 antigen on human B lymphocytes....
Journal Article Review
Advantages and applications of CAR-expressing natural killer cells.
Electronic publication date March 3, 2015
Wolfgang Glienke [...] Ulrike Koehl et al.
In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of...
Conflict of interest statement
MeSH
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •